Two compounds, one structural problem

When the Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026, six peptides received favorable recommendations for the 503A Bulks List. Four of them - BPC-157, KPV, TB-500 and MOTS-c - absorbed most of the attention. Semax and Epitalon, voted on the second day, passed by similar margins and were largely skipped over.

They deserve better treatment than they got, partly because they are genuinely interesting molecules and partly because they illustrate a problem that runs through this entire category: what happens when a compound's evidence base comes almost entirely from one laboratory network.

Neither is approved by FDA. Neither has been added to any list. The advisory votes were non-binding, and formal listing requires rulemaking that has not occurred. We covered where that process stands in our piece on what comes next for peptide regulation.

Epitalon, Epithalon, Epithalone - and Epithalamin

Start with the naming, because it is not trivial and it costs researchers real time.

Epitalon and Epithalon are the same molecule. The variation is transliteration from the Russian эпиталон, and both spellings appear widely - "Epithalon" has become more common in international commercial use, while "Epitalon" persists in translated Russian-origin publications. Epithalone shows up occasionally as a third variant. If you are searching literature and only using one spelling, you are seeing part of the record.

Epithalamin is a different substance, and this is the distinction that matters most.

Epitalon is a synthetic tetrapeptide: alanine-glutamic acid-aspartic acid-glycine, abbreviated AEDG, molecular weight roughly 390 daltons, CAS 307297-39-8. It is among the smallest peptides in the entire research literature. Epithalamin is the parent material - a low-molecular-weight polypeptide complex extracted from bovine pineal gland tissue, not a single defined sequence.

The work originates with Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology, part of a Soviet-era research program on organ-extract "bioregulators." Khavinson's team screened fragments of epithalamin and synthesized AEDG as a candidate active core.

Here is why the distinction matters commercially and scientifically. The long-running human observational cohort studies in Russian elderly populations that get cited as evidence for Epitalon were largely conducted using Epithalamin - the bovine extract - not synthetic AEDG. The two are related but they are not the same substance, and a defined tetrapeptide is not interchangeable with an undefined polypeptide complex from an animal gland. Any summary that cites those cohort results as Epitalon human data has collapsed two compounds into one.

What the record actually contains. Telomerase activation and telomere elongation have been demonstrated in human cell culture, originally by Khavinson's group in 2003 and - notably - in an independent replication reported in 2025 at Brunel University London using normal breast epithelial and fibroblast lines. That independent replication is a meaningful data point, because independent replication is precisely what most of this compound's record lacks. Rodent lifespan findings exist but are mixed and regimen-dependent. No completed controlled human trial has measured telomere length before and after administration of synthetic AEDG.

Semax: engineered from a hormone fragment

Semax has a cleaner origin story and a more unusual regulatory position.

Native ACTH - adrenocorticotropic hormone - is 39 amino acids, and its N-terminal region carries the full corticotropic activity that drives cortisol release at the melanocortin-2 receptor. Earlier neurobiology established that a shorter internal fragment, ACTH(4-10), carries neurotropic and behavioral activity independent of that corticotropic effect.

Semax is that fragment, modified. The native ACTH(4-10) sequence is Met-Glu-His-Phe-Arg-Trp-Gly. Semax is Met-Glu-His-Phe-Pro-Gly-Pro - the C-terminal Arg-Trp-Gly replaced with a Pro-Gly-Pro motif. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences.

That substitution is genuinely elegant engineering. ACTH(4-10) alone is degraded rapidly by enkephalinase, giving it a very short serum half-life. The Pro-Gly-Pro extension inhibits that degradation, substantially extending stability, while the modified sequence was reported to eliminate corticotropic activity at MC2R. And there is a further wrinkle: work published in 2024 found the Pro-Gly-Pro fragment produces effects of its own in rodent stress models, suggesting the extension is not merely a half-life stabilizer but contributes its own pharmacology.

Mechanistically, the published work centers on neurotrophins. In rat hippocampus, Semax administration has been reported to increase BDNF protein around 1.4-fold, exon III BDNF mRNA around 3-fold, and TrkB receptor phosphorylation around 1.6-fold. Additional published work reports NGF expression changes, modulation of dopaminergic and serotonergic systems, and effects in cerebral ischemia models.

Regulatory position. Semax is registered as a prescription pharmaceutical in the Russian Federation, and has been since 1994, for indications including cerebrovascular events and disorders of cognition and attention. It is not approved by FDA, EMA, or any other Western regulatory authority for any indication. The Russian registration rests on Russian-conducted clinical data that has never been submitted to or reviewed by FDA or EMA.

That is an unusual profile: decades of institutional clinical use in one jurisdiction, and effectively zero Western regulatory evaluation.

The criticism the committee voted past

FDA staff had recommended against including any of the fourteen peptide forms under review, citing short and underpowered studies insufficient to establish safety and effectiveness for the nominated uses. The committee recommended six anyway, breaking with its own scientists.

For Semax and Epitalon specifically, that criticism has a particular shape. It is not that the research is absent - for Semax there is a substantial body of it. It is that the research overwhelmingly comes from one national research tradition, published substantially in one language, with limited independent replication outside that network. For Epitalon, the majority of the published corpus traces to Khavinson's institute and its collaborators.

This is not an accusation of bad science. Single-tradition evidence bases occur for ordinary reasons - funding structures, language barriers, Cold War era research isolation. But independent replication is how a finding graduates from interesting to established, and a body of work that has not been widely replicated outside its originating network is at an earlier stage of that process than raw publication count suggests. The 2025 Brunel replication of the Epitalon telomerase finding is worth noting precisely because it is one of the few instances of this happening.

What this means if you are sourcing either compound

Two practical points follow.

Identity verification matters more than usual here. Epitalon is a four-residue peptide of roughly 390 daltons. Confirming that what is in a vial is actually AEDG - and not the parent extract, a related Khavinson peptide, or something else entirely - is a mass spectrometry question, and it is a fair thing to ask a supplier to document. The naming confusion that surrounds this compound in the marketplace is exactly the environment in which substitution goes unnoticed.

Be skeptical of summaries. Given the Epithalamin/AEDG conflation described above, and given that much of the underlying literature is translated, secondary sources about these two compounds are unusually unreliable. Content that cites human longevity outcomes for Epitalon without noting which substance was studied is a signal about that source's care generally.

Frequently asked questions

Is Epitalon the same as Epithalon?

Yes. Both spellings refer to the tetrapeptide Ala-Glu-Asp-Gly (AEDG). The variation comes from transliteration of the Russian name. Epithalone is a less common third spelling.

Is Epitalon the same as Epithalamin?

No. Epithalamin is a polypeptide complex extracted from bovine pineal gland. Epitalon is a defined synthetic tetrapeptide developed as an analog of its proposed active core. Much of the human observational data cited for Epitalon was actually generated with Epithalamin.

What is Semax derived from?

It is a modified fragment of adrenocorticotropic hormone. The ACTH(4-10) sequence was altered by replacing its C-terminal Arg-Trp-Gly with Pro-Gly-Pro, which extends metabolic stability.

Is Semax approved anywhere?

It is registered as a prescription pharmaceutical in the Russian Federation and some neighboring countries. It is not approved by FDA or EMA, and the Russian registration data has not been reviewed by either agency.

Did the July 2026 votes make these legal to compound?

No. The recommendations were advisory and non-binding. Neither compound has been added to the 503A Bulks List, and formal addition requires rulemaking that has not been completed.

Why is there so much less written about these two than about BPC-157?

Largely because their literature is older, substantially non-English, and lacks the social-media presence that drives coverage of tissue-repair compounds.

Where we stand

BioPure Peptides supplies Epithalon and Semax as research materials. Our API is synthesized at a WHO/GMP and ISO 9001 certified laboratory in California and tested to greater than 99% purity, and we will provide analytical documentation on request - which, for a 390-dalton tetrapeptide sold in a market with three spellings and a similarly named parent compound, is worth actually asking for.

Our team is in Chandler, Arizona: (888) 745-1505 or our contact page.

All products sold by BioPure Peptides are intended strictly for in-vitro laboratory and research use only. They are not for human or animal consumption. These statements have not been evaluated by the U.S. Food and Drug Administration, and these products are not intended to diagnose, treat, cure, or prevent any disease.